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S U M M A R Y
Objectives: The occurrence and dissemination of methicillin-resistant Staphylococcus aureus (MRSA) in
healthcare settings and the community and its risk of being introduced into hospitals are matters of great
concern. The purpose of this study was to conduct a miniaturized epidemiological analysis of S. aureus-
associated infections and to characterize the isolates by a variety of molecular typing techniques.
Ongoing molecular surveillance is essential to prevent S. aureus strains from becoming endemic in the
Lebanese healthcare setting.
Methods: A total of 132 S. aureus from different clinical specimens were isolated over a 6-month period.
Characterization of the isolates was done by detection of the mecA gene, Panton–Valentine leukocidin
determinant detection, staphylococcal chromosomal cassette (SCCmec) typing of MRSA, S. aureus protein
A (spa) typing, multilocus sequence typing (MLST), pulsed-ﬁeld gel electrophoresis (PFGE), and
antibiogram analysis.
Results: MRSA represented 30% of the isolates, with PVL being detected in 54% of MRSA and 12% of
methicillin-susceptible S. aureus (MSSA). A difference between MRSA and MSSA was observed in the spa
types. Clustering SCCmec with MLST identiﬁed seven MRSA and 20 MSSA clones, with PVL-positive ST80-
MRSA-IV being the dominant clone (7%), while PFGE revealed 32 groups with 80% cutoff similarity.
Conclusions: Although the results of this study are based on samples collected from one hospital, the
high diversity observed along with the lack of any equivalence in the genetic backgrounds of the major
MSSA and MRSA clones, emphasizes the urgent need for standardized surveillance combined with the
application of well-validated typing methods to assess the occurrence of MRSA and subsequently to
control its spread.
 2013 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious
Diseases. 
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Staphylococcus aureus is a major human pathogen that causes a
broad range of serious community-acquired and nosocomial
diseases in humans, from minor skin infections to severe
infections such as septicemia.1 The increasing prevalence of
methicillin-resistant S. aureus (MRSA), and its ability to spread in
the hospitals and the community, has posed a major challenge for
infection control.2 Today, although community-associated MRSA
(CA-MRSA) imposes low biological cost since it carries a small,       
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mec (SCCmec) and exhibits relative resistance to a limited number
of antimicrobial agents, it continues to be a major public health
crisis. The fast dissemination of CA-MRSA in the community and
its ability to invade hospital settings thus replacing the
traditional hospital-associated MRSA (HA-MRSA) strains, makes
the epidemiological understanding of CA-MRSA even more
complex.1,3
The Panton–Valentine leukocidin (PVL) toxin, a prophage-
encoded bicomponent pore-forming protein, has been strongly
linked epidemiologically to prevalent CA-MRSA strains, although
its role in pathogenicity remains controversial, with a number of
studies showing its association with primary skin infections and
necrotizing pneumonia, while others mitigating its signiﬁcance as
a virulence factor.1,4–7
Knowledge of epidemic MRSA clones can help in the develop-
ment of effective strategies to aid in controlling spread, optimizingociety for Infectious Diseases. Open access under CC BY-NC-SA license.
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the evolutionary process of prevalent MRSA clones through current
genotyping techniques is a crucial step to reveal relatedness
among isolates, with sequencing of protein A (spa typing), SCCmec
typing of MRSA, multilocus sequence typing (MLST), and pulsed-
ﬁeld gel electrophoresis (PFGE) being the most valuable typing
tools.
In Lebanon, there are limited data on the prevalence of S. aureus
obtained from both inpatient and outpatient populations, there is
no information on the methicillin-susceptible S. aureus (MSSA)/
MRSA population structure, and little attention has been paid to
the molecular epidemiology of this pathogen. Previous ﬁndings
from Lebanon have provided the ﬁrst snapshot of the genetic
population structure of S. aureus in the country.10 Ongoing
molecular surveillance is essential to prevent S. aureus strains
from becoming endemic in the Lebanese healthcare setting.
Accordingly, this study was conducted to better understand S.
aureus-associated infections and to characterize representative
isolates by a variety of molecular typing techniques.
2. Methods
2.1. Clinical isolates
Between May and October 2011 (6 months), a total of 132
consecutive non-duplicate S. aureus (designated HST 1–132)
clinical samples representing all cultured S. aureus isolates
recovered in the Clinical Microbiology Section of the American
University of Beirut Medical Center (AUB-MC) were collected.
AUB-MC provides tertiary services for over 300 000 patients
annually with a 350-bed inpatient capacity, occupied by an
expatriate population from all over Lebanon as well as neighboring
countries. As such, the strain diversity in the hospital is likely to
reﬂect the diversity in the region. All isolates were conﬁrmed as S.
aureus by growth on mannitol salt agar (MSA), Gram staining, and
positive catalase reaction, as well as the ability to produce
coagulase enzyme using the SLIDEX Staph Plus agglutination kit
(bioMe´rieux, France).
2.2. Statistical analysis
Categorical comparisons were performed using the Chi-square
test. A p-value of less than 0.05 was considered to be signiﬁcant.
The associations between MRSA and MSSA carriage along with
patient demographics and characteristics were evaluated using the
R statistical package (v. 3.0.1). Odds ratios (ORs) and their 95%
conﬁdence intervals (95% CIs) were also calculated. The functions
used in R included ‘‘chisq.test()’’ from the package ‘‘stats’’ and
‘‘oddsratio.wald()’’ from the package ‘‘epitools’’.
2.3. DNA extraction
DNA was extracted using the Nucleospin Tissue genomic DNA
kit (Macherey-Nagel, Germany) in accordance with the manufac-
turer’s instructions.
2.4. Molecular approaches
Ampliﬁcation of the 16S rRNA, PVL, and mecA genes was done as
described previously.11 A PVL-negative MRSA reference strain
(N315) and a PVL-positive MSSA reference strain (ATCC 49775)
were used. SCCmec elements of MRSA were typed using previously
described PCR primers.12 The conditions of the PCR were ﬁrst
optimized using the following reference strains: MRSA NCTC
10442 (SCCmec I), MRSA N315 (SCCmec II), MRSA 85/2082 (SCCmec
III), MRSA JCSC 4744 (SCCmec IVa), MRSA JCSC 2172 (SCCmec IVb),MRSA JCSC 47882 (SCCmec IVc), and MRSA WIS (SCCmec V). Typing
of the polymorphic X region of the S. aureus protein A (Spa) was
carried out by amplifying the spa gene as described previously.13,14
Thirty-six isolates representing all spa clonal clusters (spa-CCs)
were MLST-typed. Ampliﬁcation of seven housekeeping genes
(carbamate kinase (arcC), shikimate dehydrogenase (aroE), glycer-
ol kinase (glpF), guanylate kinase (gmk), phosphate acetyltransfer-
ase (pta), triose-phosphate isomerase (tpi), and acetyl coenzyme A
acetyltransferase (yqiL)) by MLST was done according to published
sequences.15 Isolates subjected to MLST typing were also typed
using PFGE. Genomic DNA was restricted with SmaI and the
resulting fragments were separated by PFGE.16
2.5. Antibiotic susceptibility testing
All isolates were tested for antibiotic resistance by Kirby–Bauer
disk diffusion method, in accordance with the standards recom-
mended by the Clinical and Laboratory Standards Institute.17
Resistance was tested against the following antibiotics: augmen-
tin, cephalothin, ciproﬂoxacin, clindamycin, erythromycin, genta-
micin, oxacillin, rifampin, teicoplanin, tetracycline, and
trimethoprim–sulfamethoxazole. All disks were obtained from
Oxoid, UK, and S. aureus ATCC 25923 was used as a quality control
strain. Isolates showing resistance to erythromycin were further
tested for inducible resistance, as described previously.18
3. Results and discussion
A total of 132 isolates recovered between May and October
2011 were characterized. Skin and soft tissue infections (SSTIs)
accounted for 42% of clinical presentations, which is consistent
with the high prevalence of SSTIs caused by S. aureus1 (Table 1).
Twenty-one MRSA isolates were PVL-positive (21/39; 54%), while
11 MSSA isolates were PVL-positive (11/93; 12%); the percentage
of MRSA PVL-positive was signiﬁcantly higher than that of the
MSSA strains (p = 8.79  107). However, signiﬁcant differences
were not detected between MRSA and MSSA with respect to
specimen origin, gender, or patient status (Table 1).
MRSA represented 30% of the isolates collected in this study,
which is signiﬁcantly lower than the percentage reported
previously (93/130; 72%) in a study from Lebanon, where a
number of randomly collected isolates from the same hospital
(AUB-MC) were partially characterized.10 It is important to note
that an infection control and prevention program (ICPP) serves the
AUB-MC to limit MRSA infections.19 Practices in this program
include, but are not limited to, standard precautions (hand
hygiene, use of gloves and gowns, appropriate handling of patient
care equipment and laundry) and contact precautions (patient
placed in a single-patient room when available, limiting patient
transport outside the room, use of disposable non-critical patient-
care equipment when necessary, frequent cleansing and disinfec-
tion of the rooms). The occurrence of MRSA among S. aureus varies
according to the geographical region, with a low frequency (1%)
in some countries in Europe (e.g., the Netherlands, Denmark, and
Sweden) and a high frequency (>60%) in countries such as the USA
and Japan.20–22
SCCmec typing revealed the prevalence of the mobile genetic
element SCCmec type IV (33/39; 85%), commonly known to be
associated with CA-MRSA infections.23–25 All MRSA isolates
harboring the SCCmec IV cassette were positive for the PVL gene,
while ﬁve (13%) harboring the SCCmec V cassette were PVL-
negative. It is noteworthy that one MRSA recovered from the
sputum of a 64-year-old female in the intensive care unit, showed
resistance to almost all tested antibiotics and harbored SCCmec III;
SCCmec III is known to be associated with HA-MRSA.25–27 Similar
results were obtained in the study conducted by Tokajian et al. in
Table 1
Patient demographics and characteristics of MRSA and MSSA isolates
Aspect MRSA (n = 39) MSSA (n = 93) p-Valuea OR (95% CI)
nb % n %
Specimen origin
Wound/cyst/abscess 17 44 39 42 0.8579 1
Respiratory 12 31 33 35 1.19 (0.50–2.86)
Otherc 10 26 21 23 0.91 (0.35–2.35)
Sex
Male 26 67 58 62 0.7869 1
Female 13 33 35 38 0.828 (0.37–1.82)
Patient
Inpatient 22 56 49 53 0.8415 1.162 (0.54–2.46)
Outpatient 17 44 44 47 1
PVL
Positive 21 54 11 12 8.79  107 8.696 (3.57–21.18)
Negative 18 46 82 88 1
MRSA, methicillin-resistant Staphylococcus aureus; MSSA, methicillin-susceptible Staphylococcus aureus; OR, odds ratio; CI, conﬁdence interval; PVL, Panton–Valentine
leukocidin gene.
a Chi-square.
b Numbers are rounded up.
c Others: aspirates, ear, joint ﬂuid, urine, blood, catheter.
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isolates.10 PVL along with SCCmec type IV are markers for CA-MRSA
infections in Europe and the USA,28–30 and having PVL-positive
MRSA with type IV SCCmec is in agreement with previous
studies.10,31–33 The detection of PVL-negative MRSA carrying type
V SCCmec is also in concordance with several other studies
conducted in Lebanon and elsewhere.10,33–36
The isolates investigated in this study (n = 132) were assigned
to 71 different spa types, with the most common being t021 (6%),
t044 (5%), and t267 (5%). Fifty-three different spa types wereFigure 1. Population snapshot based on BURP analysis of 132 isolates. BURP grouping us
singletons, and four excluded spa types. Each dot represents a unique spa type. The diame
represent group founders, deﬁned as the spa type(s) with the highest founder score widentiﬁed in the MSSA isolates (n = 93) compared to 25 in the
MRSA isolates (n = 39). Using the ‘based upon repeat pattern’
(BURP) algorithm, spa types were clustered into 40 different
groups, with 15 groups comprising more than one spa type and 25
so-called singletons (Figure 1). The most prevalent spa type within
the MRSA population was spa t044 (5/39; 13%), which is in
agreement with other studies from within the region (Jordan and
Lebanon),10,33 as well as in Europe.37 However, spa t021 (7/93; 8%)
was the predominant type within the MSSA isolates, and this
differs from previous ﬁndings.10,33 spa t021 has been detected ining default parameters resulted in 15 spa-CCs with eight having group founders, 25
ter of the dot is proportional to the quantity of the corresponding spa type. Blue dots
ithin a CC, while yellow dots represents major subgroup founders.
Table 2
Molecular characteristics of the nine novel spa types detected in this study
spa type Number found among isolates mecA PVL Ridom repeat succession spa-CC
t9804 1 MSSA Neg 08–16–34–02–43–34–16–16–34–02–16 Singletons
t9805 2 MSSA
MSSA
Pos
Neg
26–22–10–17–20–17–12 Singletons
t9806 1 MSSA Neg 7–17–12–23–02–12–23 No founder
t9127 1 MSSA Neg 07–23–12–34–34–12–36–23–02–12–23 84
t9128 1 MSSA Neg 26–23–34–23–31–05–17–17–25–16–28 Singletons
t9129 1 MSSA Neg 7–16–21–17–34–34–34–33–34 267
t9830 1 MSSA Neg 04–17–34–17–32–23–24–24 Singletons
t9831 2 MRSA Neg 07–23–12–12–20–17–12–12–12 No founder
t9832 2 MRSA Neg 125–13–23–31–29–25–17–25–16–28 Singletons
mecA, methicillin resistance encoding gene; PVL, Panton–Valentine leukocidin gene; spa-CC, spa clonal complex; MSSA, methicillin-susceptible Staphylococcus aureus; MRSA,
methicillin-resistant Staphylococcus aureus.
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Europe.37,38 Finally, 12 isolates were assigned to nine new spa
types assigned by Ridom StaphType software (http://spaserver.ri-
dom.de/) (Table 2).
Thirty-six isolates consisting of 11 MRSA and 25 MSSA were
MLST-typed. The isolates were chosen to represent all the 15 spa-
CC groups, ﬁve of the singletons, and one of the excluded isolates
(Table 3). There were seven major MRSA clones deﬁned as isolates
with the same sequence type (ST) and SCCmec type. These clonesTable 3
Overview of representative MRSA and MSSA spa types and their corresponding
MLST clones
Clonea MLST-CC spa type (number of isolates) spa-CC PVL
ST5-MRSA-IV 5 t002 (2) 306/002 Neg
ST5-MRSA-IV 5 t214 (2) 306/002 Neg
ST6-MSSA 6 t304 (4) 304/121 Neg
ST361-MSSA 361 t315 (2) 306/002 Neg
ST199-MSSA 15 t084 (4) 084 Neg
ST199-MSSA 15 t9210 (1) 084 Neg
ST15-MSSA 15 t774 (1) 084 Neg
ST8-MSSA 8 t008 (2) 304/121 Pos
ST30-MSSA 30 t012 (1) 021 Neg
ST30-MSSA 30 t021 (7) 021 Pos
ST30-MRSA-IV 30 t019 (2) 021 Pos
ST34-MSSA 30 t2096 (1) No founder Neg
ST34-MSSA 30 t166 (2) No founder Neg
ST80-MRSA-IV 80 t021 (1) 021 Neg
ST80-MRSA-IV 80 t044 (5) 044 Pos
ST80-MRSA-IV 80 t131 (3) 044 Pos
ST80-MRSA-IV 80 t6476 (1) sg No. 9 Pos
ST720-MSSA 121 t659 (1) No founder Neg
ST1-MSSA 1 t127 (5) sg No. 3 Neg
ST22-MRSA-IV 22 t9832 (2) sg No. 15 Neg
ST508-MSSA 45 t861 (1) sg No. 7 Neg
ST46-MSSA 45 t132 (2) Excluded Neg
ST88-MSSA 88 t186 (2) 186/786/690 Neg
ST72-MRSA-IV 72 t3468 (1) No founder Neg
ST72-MRSA-V 72 t9831 (2) No founder Neg
ST97-MSSA 97 t9129 (1) 267 Neg
ST97-MSSA 97 t044 (1) 044 Neg
ST291-MSSA 398 t937 (1) No founder Neg
ST291-MSSA 398 t1149 (5) No founder Neg
ST7-MSSA 7 t091 (5) No founder Neg
ST789-MSSA 789 t9806 (1) No founder Neg
ST770-MSSA 770 t377 (2) sg No. 5 Neg
ST641-MSSA 641 t005 (2) 032 Neg
ST25-MSSA 25 t078 (1) No founder Neg
ST239-MRSA-III 239 t037 (1) 021 Neg
ST1995-MSSA 25 t349 (1) No founder Neg
MRSA, methicillin-resistant Staphylococcus aureus; MSSA, methicillin-susceptible
Staphylococcus aureus; MLST, multilocus sequence typing; spa-CC, spa clonal
complex; MLST-CC, multilocus sequence type clonal complex; PVL, Panton–
Valentine leukocidin gene; sg, singleton.
a Thirty-six strains were typed by MLST representing all 15 spa-CC groups, ﬁve of
the singletons, and one of the excluded isolates.were associated with complexes CC5, CC22, CC30, CC72, CC80, and
CC239. On the other hand, 20 MSSA clones were identiﬁed and
these were associated with complexes CC1, CC6, CC7, CC8, CC15,
CC25, CC30, CC45, CC88, CC97, CC121, CC361, CC398, CC641,
CC770, and CC789. Twenty-ﬁve allelic proﬁles were generated
with the most prevalent STs being ST80 (4/36; 11%) and ST30 (3/
36; 8%), which is in agreement with previous results from Lebanon,
Jordan, Kuwait, and other neighboring countries.10,33,39–41
Clustering SCCmec with MLST identiﬁed seven MRSA and 20
MSSA clones, with PVL-positive ST80-MRSA-IV being the dominant
clone (9/36; 7%), followed by PVL-positive ST30-MSSA (7/36; 5%)
(Table 3). The predominance of the ST80 clone has previously been
reported in the region,33,39–42 while ST30-MSSA, known as the
Southwest Paciﬁc clone, has been shown to prevail in other areas,
in particular Kuwait, Abu Dhabi, the UK, Germany, and Australia,2
and to probably have been introduced through air travel. One
strain among the ST80-IV was PVL-negative harboring spa type
t021; this is not common within CC80, as it is usually associated
with strains belonging to CC30 (http://spaserver2.ridom.de/spa-
t021.shtml).43
All isolates typed using PFGE were typeable by SmaI macro-
restriction and produced different pulsotypes according to
previously deﬁned standards.44 Thirty-two groups were deﬁned
by employing an 80% similarity cutoff value, with only two groups
containing more than one isolate. Clusters were designated with
numbers from 1 to 32 (Figure 2). Typing results combining MLST
and PFGE showed that several isolates belonging to the same MLST
CC were assigned to different PFGE clusters; CC30 and CC80 strains
were present in more than one PFGE cluster. On the other hand,
strains belonging to the same PFGE cluster generally belonged to
the same MLST CC (e.g., CC15). Similarly, isolates harboring the
same spa types were found to belong to distinct PFGE clusters: t021
belonging to PFGE types 9 and 28, and t044 belonging to PFGE
types 12 and 19. Of note, PFGE grouped isolates belonging to the
same spa-CCs as genetically close (spa-CC 084 were assigned to
PFGE types 3 and 4). This could indicate higher diversity being
detected with the use of PFGE compared to that deﬁned by spa
typing and/or MLST, making PFGE the ‘gold standard’ typing
technique.45,46 Although, PFGE is highly reproducible and remains
an important tool for micro- and macro-epidemiological surveys,
the technique suffers from several disadvantages. These include:
the high cost during outbreaks, technical challenges, it is time-
consuming and labor intensiveness, and it requires complex inter-
laboratory exchange of results; the hampered typeability of
isolates with methylated SmaI sites is also a drawback.47,48
Seventy-four (56%) out of the 132 isolates were sensitive to all
tested antibiotics. Among the remaining 58 (44%), resistance was
detected to one or more of the antibiotics used. According to the
deﬁnitions proposed by Magiorakos et al.,49 22% of the isolates
were multidrug-resistant (MDR) bacteria by being MRSA and 5%
Figure 2. Dendrogram of PFGE clusters and genotypic relationships of Staphylococcus aureus isolates. SmaI macrorestriction patterns were analyzed using the Dice coefﬁcient
and visualized by unweighted pair-group method, using average linkages with 1% tolerance and 1% optimization settings. The similarity cutoff of 80% is indicated by the
vertical line. PFGE groups determined by cluster analysis are numbered from 1 to 32. The spa types, spa-CC, ST types, and MLST-CC are also included.
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or more antimicrobial categories. Only two isolates (1.5%) were
extensively drug-resistant (XDR) with the possibility of being
pandrug-resistant (PDR) for being non-susceptible to one or more
agents in all but two or fewer antimicrobial categories. Moreover,
the major resistance proﬁle detected within the MSSA included
resistance to clindamycin and erythromycin (6/93; 6%), with allTable 4
Distribution of antimicrobial resistance proﬁles observed among MRSA and MSSA
Resistance proﬁle (%) Number
among MSSA
Number
among MRSA
CIP (1.5) 2 -
CIP, DA (0.8) 1 -
CIP, ERY (0.8) 1 -
CIP, TET (0.8) 1 -
DA, ERY (4.5) 6 -
DA, ERY, TET (0.8) 1 -
ERY (0.8) 1 -
SXT, TET (0.8) 1 -
TET (3.8) 5 -
AUG, CIP, DA, ERY, KF, OXA (2.3) - 3
AUG, CIP, DA, ERY, KF, OXA, SXT, TET (0.8) - 1
AUG, CIP, ERY, KF, OXA (0.8) - 1
AUG, DA, ERY, KF, OXA, TET (1.5) - 2
AUG, ERY, KF, OXA (0.8) - 1
AUG, KF, OXA (16.6) - 22
AUG, KF, OXA, TET (6.8) - 9
MRSA, methicillin-resistant Staphylococcus aureus; MSSA, methicillin-susceptible
Staphylococcus aureus; AUG, augmentin; CIP, ciproﬂoxacin; DA, clindamycin; ERY,
erythromycin; KF, cephalothin; OXA, oxacillin; SXT, trimethoprim–sulfamethoxa-
zole; TET, tetracycline.strains showing an inducible clindamycin resistance. However, all
isolates were sensitive to teicoplanin, vancomycin, and rifampin.
Table 4 summarizes the percentages of the 16 generated antibiotic
resistance proﬁles in this study, as well as their distribution
between MRSA and MSSA.
In conclusion, genotype analyses showed a high diversity and a
varied range of spa types in both MSSA and MRSA isolates. The high
diversity along with the lack of any equivalence in the genetic
backgrounds of the major MSSA and MRSA clones could be
indicative of MRSA clones being imported instead of arising from
successful MSSA clones and warrants further study.
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